Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Single-cell genotyping of MDS/CMML clonal output, VTE risk in diffuse glioma, and Del(1p32) is an adverse prognostic factor in myeloma

    Single-cell genotyping of MDS/CMML clonal output, VTE risk in diffuse glioma, and Del(1p32) is an adverse prognostic factor in myeloma

    FromBlood Podcast

    Start listeningView podcast show

    Single-cell genotyping of MDS/CMML clonal output, VTE risk in diffuse glioma, and Del(1p32) is an adverse prognostic factor in myeloma

    FromBlood Podcast

    ratings:
    Length:
    21 minutes
    Released:
    Mar 16, 2023
    Format:
    Podcast episode

    Description

    In this week’s episode we’ll discuss how azacytidine therapy influences the contributions of mutated HSC clones to hematopoiesis in MDS and CMML, learn more about the risk of venous thromboembolism in patients with adult-type diffuse glioma, and discuss the importance of 1p32 deletions as an independent and adverse prognostic factor in myeloma.
    Released:
    Mar 16, 2023
    Format:
    Podcast episode

    Titles in the series (100)

    The Blood Podcast summarizes content recently published in Blood the most cited peer-reviewed publication in the field of hematology.